|
1
|
A phase 2 study of bortezomib in relapsed, refractory myeloma.
|
N Engl J Med
|
2003
|
16.11
|
|
2
|
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
|
Blood
|
2012
|
5.11
|
|
3
|
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
|
Blood
|
2007
|
3.67
|
|
4
|
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
|
J Clin Oncol
|
2006
|
3.60
|
|
5
|
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
|
Blood
|
2011
|
3.58
|
|
6
|
Proteasome inhibitors in multiple myeloma: 10 years later.
|
Blood
|
2012
|
2.77
|
|
7
|
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
|
Blood
|
2012
|
2.41
|
|
8
|
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
|
N Engl J Med
|
2015
|
2.39
|
|
9
|
Targeting the p27 E3 ligase SCF(Skp2) results in p27- and Skp2-mediated cell-cycle arrest and activation of autophagy.
|
Blood
|
2008
|
2.36
|
|
10
|
Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer.
|
Cancer Res
|
2002
|
2.33
|
|
11
|
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors.
|
Blood
|
2008
|
2.22
|
|
12
|
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.
|
Clin Cancer Res
|
2009
|
2.17
|
|
13
|
The proteasome as a target for cancer therapy.
|
Clin Cancer Res
|
2003
|
2.13
|
|
14
|
American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.
|
J Clin Oncol
|
2007
|
2.09
|
|
15
|
Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.
|
Br J Haematol
|
2013
|
2.01
|
|
16
|
The proteasome and proteasome inhibitors in cancer therapy.
|
Annu Rev Pharmacol Toxicol
|
2006
|
1.99
|
|
17
|
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).
|
Blood
|
2013
|
1.98
|
|
18
|
Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
|
Blood
|
2005
|
1.95
|
|
19
|
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
|
Blood
|
2013
|
1.89
|
|
20
|
Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy.
|
Cancer
|
2011
|
1.61
|
|
21
|
Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
|
Blood
|
2012
|
1.58
|
|
22
|
Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.
|
J Biol Chem
|
2010
|
1.55
|
|
23
|
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.
|
J Clin Oncol
|
2014
|
1.52
|
|
24
|
Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
|
Cancer
|
2005
|
1.50
|
|
25
|
Chromosome 8q24.1/c-MYC abnormality: a marker for high-risk myeloma.
|
Leuk Lymphoma
|
2014
|
1.48
|
|
26
|
An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
1.48
|
|
27
|
Phase II trial of neoadjuvant chemotherapy with docetaxel followed by epirubicin in stage II/III breast cancer.
|
Breast Cancer Res Treat
|
2005
|
1.45
|
|
28
|
Mitogen-activated protein kinase phosphatase-1 is a mediator of breast cancer chemoresistance.
|
Cancer Res
|
2007
|
1.33
|
|
29
|
Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
|
Clin Cancer Res
|
2007
|
1.26
|
|
30
|
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.
|
Blood
|
2012
|
1.25
|
|
31
|
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
|
Blood
|
2013
|
1.21
|
|
32
|
Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
|
Clin Cancer Res
|
2013
|
1.19
|
|
33
|
A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma.
|
Br J Haematol
|
2013
|
1.17
|
|
34
|
Novel approaches to treatment of double-refractory multiple myeloma.
|
Am Soc Clin Oncol Educ Book
|
2013
|
1.16
|
|
35
|
Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
|
Cancer
|
2008
|
1.13
|
|
36
|
Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
|
Br J Haematol
|
2008
|
1.12
|
|
37
|
Bortezomib and EGCG: no green tea for you?
|
Blood
|
2009
|
1.11
|
|
38
|
Repression of mitogen-activated protein kinase (MAPK) phosphatase-1 by anthracyclines contributes to their antiapoptotic activation of p44/42-MAPK.
|
J Pharmacol Exp Ther
|
2003
|
1.10
|
|
39
|
A practical update on the use of bortezomib in the management of multiple myeloma.
|
Oncologist
|
2006
|
1.09
|
|
40
|
Evidence that mitogen-activated protein kinase phosphatase-1 induction by proteasome inhibitors plays an antiapoptotic role.
|
Mol Pharmacol
|
2004
|
1.06
|
|
41
|
Proteasome inhibitors induce a p38 mitogen-activated protein kinase (MAPK)-dependent anti-apoptotic program involving MAPK phosphatase-1 and Akt in models of breast cancer.
|
Breast Cancer Res Treat
|
2006
|
1.06
|
|
42
|
Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors.
|
Br J Haematol
|
2009
|
1.05
|
|
43
|
Effect of long-term storage in TRIzol on microarray-based gene expression profiling.
|
Cancer Epidemiol Biomarkers Prev
|
2010
|
1.04
|
|
44
|
p38 MAPK in myeloma cells regulates osteoclast and osteoblast activity and induces bone destruction.
|
Cancer Res
|
2012
|
1.02
|
|
45
|
HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.
|
Blood
|
2011
|
1.01
|
|
46
|
Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma.
|
Leuk Lymphoma
|
2011
|
1.01
|
|
47
|
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
|
Clin Cancer Res
|
2008
|
0.99
|
|
48
|
CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
|
Cancer Res
|
2012
|
0.97
|
|
49
|
The immunoproteasome as a target in hematologic malignancies.
|
Semin Hematol
|
2012
|
0.97
|
|
50
|
Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma.
|
Br J Haematol
|
2011
|
0.95
|
|
51
|
A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
|
Cancer Chemother Pharmacol
|
2008
|
0.94
|
|
52
|
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors.
|
Cancer
|
2006
|
0.94
|
|
53
|
Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation.
|
Clin Cancer Res
|
2014
|
0.93
|
|
54
|
Future agents and treatment directions in multiple myeloma.
|
Expert Rev Hematol
|
2013
|
0.92
|
|
55
|
Osteoblastic niche supports the growth of quiescent multiple myeloma cells.
|
Blood
|
2014
|
0.91
|
|
56
|
Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin.
|
Ann Hematol
|
2010
|
0.90
|
|
57
|
Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.
|
Hematol Oncol
|
2006
|
0.89
|
|
58
|
Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.
|
Mol Cancer Ther
|
2012
|
0.89
|
|
59
|
The zinc finger transcription factor ZKSCAN3 promotes prostate cancer cell migration.
|
Int J Biochem Cell Biol
|
2012
|
0.89
|
|
60
|
Evidence for involvement of calpain in c-Myc proteolysis in vivo.
|
Arch Biochem Biophys
|
2002
|
0.88
|
|
61
|
Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.
|
Ann Hematol
|
2006
|
0.87
|
|
62
|
Targeting the ubiquitin-proteasome pathway in breast cancer therapy.
|
Future Oncol
|
2006
|
0.87
|
|
63
|
Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma.
|
Clin Lymphoma Myeloma Leuk
|
2013
|
0.87
|
|
64
|
Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
|
Am J Hematol
|
2012
|
0.86
|
|
65
|
Rapid early monoclonal protein reduction after therapy with bortezomib or bortezomib and pegylated liposomal doxorubicin in relapsed/refractory myeloma is associated with a longer time to progression.
|
Cancer
|
2011
|
0.86
|
|
66
|
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
|
Cancer
|
2011
|
0.86
|
|
67
|
Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo.
|
Mol Cancer Ther
|
2010
|
0.86
|
|
68
|
Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment.
|
Clin Lymphoma Myeloma
|
2008
|
0.85
|
|
69
|
A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.
|
Biol Blood Marrow Transplant
|
2013
|
0.85
|
|
70
|
Electroacupuncture for thalidomide/bortezomib-induced peripheral neuropathy in multiple myeloma: a feasibility study.
|
J Hematol Oncol
|
2014
|
0.83
|
|
71
|
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.
|
Eur J Haematol
|
2011
|
0.83
|
|
72
|
Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer.
|
Clin Breast Cancer
|
2010
|
0.83
|
|
73
|
Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma.
|
Biol Blood Marrow Transplant
|
2013
|
0.83
|
|
74
|
Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia.
|
Am J Hematol
|
2002
|
0.82
|
|
75
|
The novel anticancer agent JNJ-26854165 induces cell death through inhibition of cholesterol transport and degradation of ABCA1.
|
J Pharmacol Exp Ther
|
2013
|
0.81
|
|
76
|
The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma.
|
Leuk Lymphoma
|
2013
|
0.81
|
|
77
|
Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma.
|
Ther Clin Risk Manag
|
2009
|
0.81
|
|
78
|
Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions.
|
Int J Cancer
|
2014
|
0.80
|
|
79
|
Emerging data on the use of anthracyclines in combination with bortezomib in multiple myeloma.
|
Clin Lymphoma Myeloma
|
2007
|
0.80
|
|
80
|
Efficacy and safety of pegylated liposomal Doxorubicin in combination with bortezomib for multiple myeloma: effects of adverse prognostic factors on outcome.
|
Clin Lymphoma Myeloma Leuk
|
2011
|
0.79
|
|
81
|
Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma.
|
Leuk Lymphoma
|
2014
|
0.78
|
|
82
|
Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis.
|
Cancer
|
2014
|
0.77
|
|
83
|
Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms.
|
Arch Pathol Lab Med
|
2013
|
0.77
|
|
84
|
An unusual case of aggressive systemic mastocytosis with associated refractory plasma cell myeloma.
|
Clin Lymphoma Myeloma Leuk
|
2012
|
0.76
|
|
85
|
Emerging role of novel combinations for induction therapy in multiple myeloma.
|
Clin Lymphoma Myeloma
|
2006
|
0.76
|
|
86
|
The future of proteasome inhibitors in relapsed/refractory multiple myeloma.
|
Oncology (Williston Park)
|
2011
|
0.75
|
|
87
|
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
|
Cancer Med
|
2014
|
0.75
|
|
88
|
Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma.
|
Ann Hematol
|
2015
|
0.75
|